CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells

Molecular Therapy: Oncology · Published 2026-08-03 · DOI 10.1016/j.omton.2026.201297

Free full text

Authors (4)

Audrey C. Bochi-Layec, Ivan J. Cohen, Jean Lemoine, Marco Ruella

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Bochi-Layec, A., Cohen, I., Lemoine, J., et al. (2026). CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells. Molecular Therapy: Oncology. https://doi.org/10.1016/j.omton.2026.201297

Related articles

• Rethinking lymphodepleting preconditioning in adoptive T cell therapy for durable tumor control · Molecular Therapy: Oncology · 2026 · Same journal
• Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy · Molecular Therapy: Oncology · 2026 · Same journal
• AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer · Molecular Therapy: Oncology · 2026 · Same journal
• CART-immune-related adverse events after BCMA CAR-T therapy · Molecular Therapy: Oncology · 2026 · Same journal
• Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance · Molecular Therapy: Oncology · 2026 · Same journal
• Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis · Molecular Therapy: Oncology · 2026 · Same journal
• Synergistic Cell-Cycle Repression by HDAC/EZH2 Co-Targeting in H3K27-Altered Diffuse Midline Glioma · Molecular Therapy: Oncology · 2026 · Same journal
• Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity · Molecular Therapy: Oncology · 2026 · Same journal
• CAR design equips diverse immune cells with unique antigen-specific activation identities · Molecular Therapy: Oncology · 2026 · Same journal
• Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations · Molecular Therapy: Oncology · 2026 · Same journal